Lepodisiran for atherosclerosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 May 2026: Trial registered, NCT07613294
  2. 1 Jun 2026: Trial started, NCT07613294

The trials

NCT07613294: A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

State
Under way
Phase
Phase 3
People
252 planned
Started
1 Jun 2026
Primary completion
Dec 2029
Arms
Lepodisiran
Results
None posted
  1. 29 May 2026: Trial registered
  2. 1 Jun 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.